RECRUITING

Dime La VerDAD: Verify, Debunk, and Disseminate

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Dime La VerDAD is an innovative social media capacity-building program that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, "promotores de salud" from the Hispanic community as trusted messengers to debunk vaccination misinformation. The study will leverage existing community relationships in Chicago and a first of its kind misinformation curriculum to debunk misinformation in communities served by participating promotores de salud. Dime La VerDAD (Verify, Debunk, and Disseminate) is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. This mixed methods study will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in infodemiology, 2) evaluate how debunking misinformation is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can lead to changes in opinions and behavior (vaccination rates) about COVID and influenza vaccines among Chicago's predominantly Hispanic communities.

Official Title

Dime La VerDAD: Verify, Debunk, and Disseminate

Quick Facts

Study Start:2024-07-02
Study Completion:2028-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06417762

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. *
  1. * Exclusion: Plans to stop working as a "promotor" before spring of 2027 (end of data collection planned). People can not participate if they are under the age of 18, or can not understand Spanish and English, or do not provide services in the included zip codes, or do not wish to participate in social media.

Contacts and Locations

Study Contact

Yajaira Bolanos Flores, MPH
CONTACT
(319) 353-8785
yajaira-bolanosflores@uiowa.edu

Principal Investigator

Marina DelRios, MD
PRINCIPAL_INVESTIGATOR
University of Chicago - Section of Emergency Medicine

Study Locations (Sites)

Rush University
Chicago, Illinois, 60612
United States
University of Chicago
Chicago, Illinois, 60637
United States
University of Iowa
Iowa City, Iowa, 52242
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States

Collaborators and Investigators

Sponsor: University of Chicago

  • Marina DelRios, MD, PRINCIPAL_INVESTIGATOR, University of Chicago - Section of Emergency Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-02
Study Completion Date2028-04-01

Study Record Updates

Study Start Date2024-07-02
Study Completion Date2028-04-01

Terms related to this study

Additional Relevant MeSH Terms

  • Misinformation
  • Influenza
  • COVID-19
  • Vaccine Hesitancy
  • Communication Research
  • Health Behavior